These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 25188033)

  • 21. Analysis of the second generation antidepressant venlafaxine and its main active metabolite O-desmethylvenlafaxine in human plasma by HPLC with spectrofluorimetric detection.
    Mandrioli R; Mercolini L; Cesta R; Fanali S; Amore M; Raggi MA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Sep; 856(1-2):88-94. PubMed ID: 17581798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determination of venlafaxine and its active metabolite O-desmethylvenlafaxine in human plasma by HPLC fluorescence.
    Shen S; Zhang C; Mao Y
    Gen Psychiatr; 2018; 31(2):e000010. PubMed ID: 30582123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Venlafaxine serum levels and CYP2D6 genotype.
    Veefkind AH; Haffmans PM; Hoencamp E
    Ther Drug Monit; 2000 Apr; 22(2):202-8. PubMed ID: 10774634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simultaneous quantitation of venlafaxine and its main metabolite, O-desmethylvenlafaxine, in human saliva by HPLC.
    Dziurkowska E; Wesolowski M
    J Sep Sci; 2013 Jun; 36(11):1726-33. PubMed ID: 23495235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Time course of clinical response to venlafaxine: relevance of plasma level and chirality.
    Gex-Fabry M; Balant-Gorgia AE; Balant LP; Rudaz S; Veuthey JL; Bertschy G
    Eur J Clin Pharmacol; 2004 Feb; 59(12):883-91. PubMed ID: 14704834
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced clearance of venlafaxine in a combined treatment with quetiapine.
    Paulzen M; Schoretsanitis G; Hiemke C; Gründer G; Haen E; Augustin M
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jul; 85():116-121. PubMed ID: 29702137
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The comparison of brand-name and generic formulations of venlafaxine: a therapeutic drug monitoring analysis.
    Unterecker S; Proft F; Riederer P; Lauer M; Deckert J; Pfuhlmann B
    Ther Drug Monit; 2014 Apr; 36(2):269-72. PubMed ID: 24365982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Field and laboratory studies of the fate and enantiomeric enrichment of venlafaxine and O-desmethylvenlafaxine under aerobic and anaerobic conditions.
    Gasser G; Pankratov I; Elhanany S; Werner P; Gun J; Gelman F; Lev O
    Chemosphere; 2012 Jun; 88(1):98-105. PubMed ID: 22445391
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.
    Shams ME; Arneth B; Hiemke C; Dragicevic A; Müller MJ; Kaiser R; Lackner K; Härtter S
    J Clin Pharm Ther; 2006 Oct; 31(5):493-502. PubMed ID: 16958828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of venlafaxine in treatment responders and non-responders: a retrospective analysis of a large naturalistic database.
    Schoretsanitis G; Haen E; Gründer G; Hiemke C; Endres K; Ridders F; Correll CU; Paulzen M
    Eur J Clin Pharmacol; 2019 Aug; 75(8):1109-1116. PubMed ID: 30968172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
    Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
    J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of renal disease on the disposition of venlafaxine.
    Troy SM; Schultz RW; Parker VD; Chiang ST; Blum RA
    Clin Pharmacol Ther; 1994 Jul; 56(1):14-21. PubMed ID: 8033490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and tolerability of venlafaxine extended release in patients with major depressive disorder.
    Plesnicar BK
    Psychiatr Danub; 2010 Sep; 22(3):413-7. PubMed ID: 20856184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine.
    Grözinger M; Dragicevic A; Hiemke C; Shams M; Müller MJ; Härtter S
    Pharmacopsychiatry; 2003 Jan; 36(1):3-6. PubMed ID: 12649767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics.
    Klamerus KJ; Parker VD; Rudolph RL; Derivan AT; Chiang ST
    Pharmacotherapy; 1996; 16(5):915-23. PubMed ID: 8888087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Duloxetine enters the brain - But why is it not found in the cerebrospinal fluid.
    Paulzen M; Gründer G; Veselinovic T; Wolf B; Hiemke C; Lammertz SE
    J Affect Disord; 2016 Jan; 189():159-63. PubMed ID: 26437230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid high-performance liquid chromatographic measurement of venlafaxine and O-desmethylvenlafaxine in human plasma. Application to management of acute intoxications.
    Matoga M; Pehourcq F; Titier K; Dumora F; Jarry C
    J Chromatogr B Biomed Sci Appl; 2001 Sep; 760(2):213-8. PubMed ID: 11530979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting.
    Reis M; Lundmark J; Björk H; Bengtsson F
    Ther Drug Monit; 2002 Aug; 24(4):545-53. PubMed ID: 12142641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LC-MS/MS method for the determination of nine antidepressants and some of their main metabolites in oral fluid and plasma. Study of correlation between venlafaxine concentrations in both matrices.
    de Castro A; Concheiro M; Quintela O; Cruz A; López-Rivadulla M
    J Pharm Biomed Anal; 2008 Sep; 48(1):183-93. PubMed ID: 18602787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of age, sex, smoking and co-medication on serum levels of venlafaxine and O-desmethylvenlafaxine under naturalistic conditions.
    Unterecker S; Hiemke C; Greiner C; Haen E; Jabs B; Deckert J; Pfuhlmann B
    Pharmacopsychiatry; 2012 Sep; 45(6):229-35. PubMed ID: 22426847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.